Cat. No. 0553
Chemical Name: 1-(2-Methoxyphenyl)-4-(4-phthalimid
Biological Activity5-HT1A antagonist.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Douris (1992) Effects of the putative 5-HT1A receptor antagonist NAN-190 on free feeding and on feeding induced by the 5-HT1A receptor agonist 8-OH-DPAT in the rat. Eur.J.Pharmacol. 219 105. PMID: 1397037.
Glennon et al (1988) Arylpiperazine derivatives as high affinity 5-HT1A serotonin ligands. J.Med.Chem. 31 1968. PMID: 3172131.
Williams and Glennon (1988) NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur.J.Pharmacol. 154 339. PMID: 2976673.
If you know of a relevant reference for NAN-190 hydrobromide please let us know.
Citations are publications that use Tocris products. Selected citations for NAN-190 hydrobromide include:
Demarque and (2010) Activity-dependent expression of Lmx1b regulates specification of serotonergic neurons modulating swimming behavior. Neuron 67 321. PMID: 20670838.
Pagano et al (2008) Gαo/i-stimulated proteosomal degradation of RGS20: a mechanism for temporal integration of Gs and Gi pathways. Physiol Behav 20 1190. PMID: 18407463.
Do you know of a great paper that uses NAN-190 hydrobromide from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: NAN-190 hydrobromide, supplier, 5-HT1A, antagonists, Serotonin, Receptors, 5-HT1, NAN190, Tocris Bioscience, 5-HT1A Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent 5-HT1A partial agonist and SSRI; antidepressant
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.